Bristol-Myers Squibb Articles

STRATEGIES TO ACHIEVE CRITICAL MASS

20 April 1992

STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB

20 April 1992

TRIAL COULD BOOST VIDEX ACCEPTANCE

20 April 1992

STOCK MARKET COMMENTARY: NEW YORK

13 April 1992

FORTHCOMING MEETINGS

13 April 1992

US RESISTANCE TO DRUG PRICE RISES

13 April 1992

GYNEX TO MARKET DELATESTRYL

13 April 1992

TEN YEARS OF ACE INHIBITION

23 March 1992

HYPOLIPIDEMICS INFO

23 March 1992

STRONGER WARNINGS ON ACE INHIBITORS

23 March 1992

US PRESCRIPTION PRICES UP 8.1%IN 1991

23 March 1992

VOLUME GROWTH FOR US DRUGMAKERS

9 March 1992

MERCK AFFIRMS SAFETY of MEVACOR

9 March 1992

AIDS TREATMENT FROM JOHNSON MATTHEY

17 February 1992

HIV POPULATIONS "ARE STABILIZING"

17 February 1992

B-MS SCHOOL OF PUBLIC HEALTH

10 February 1992

NEW CHEMICAL ENTITIES UPDATE FOR 1991

10 February 1992

STOCK MARKET COMMENTARY: NEW YORK

10 February 1992

MS&D GREECE SALES RISE 19%

3 February 1992

VESTAR'S AMBISOME LAUNCHED IN THE UK

3 February 1992

B-M SQUIBB GIVES HEART DRUGS FREE TO POOR

3 February 1992

STOCK MARKET COMMENTARY: NEW YORK

3 February 1992

APPOINTMENTS AT BRISTOL-MYERS SQUIBB

3 February 1992

NEW US PATENTS FOR TLC

27 January 1992

1991 A YEAR OF STRONG GROWTH IN THE USA

27 January 1992

TRIAL RESULTS WITH ROBERTS' AGRELIN

27 January 1992

FISONS UPDATES ON LEAD R&D PRODUCTS

27 January 1992

B-MS' VIDEX FILED IN JAPAN

27 January 1992

CAST EFFECTS ON ANTI-ARRHYTHMICS

20 January 1992

STOCK MARKET COMMENTARY: NEW YORK

20 January 1992

DECEMBER US APPROS REVIEWED

20 January 1992

US FDA BEATS 1990 DRUG APPROVALS IN 1991

13 January 1992

STOCK MARKET COMMENTARY: NEW YORK

13 January 1992

B-M SQUIBB CUTS HEALTH PROGRAM DRUG PRICES

13 January 1992

CELTRIX TO BECOME MAJOR BIOTECH PLAYER

13 January 1992

ANALGESICS IN THE USA -- AN OPEN DOOR FOR P&G?

6 January 1992

WORLD OTC MARKETS STUDIED

6 January 1992

CHANGES AHEAD FOR Rx PHARMA INDUSTRY?

6 January 1992

SB JOINS MERCK TO MARKET ZOCOR

6 January 1992

Medical claims for GI events by patients on antiplatelet therapy